1)Long JM, Holtzman DM: Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179: 312-339, 2019
2)Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356, 2002
3)Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, et al: Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367: 795-804, 2012
4)Ono K, Watanabe-Nakayama T: Aggregation and structure of amyloid β-protein. Neurochem Int 151: 105208, 2021[doi: 10.1016/j.neuint.2021.105208]
5)Ono K: Alzheimer's disease as oligomeropathy. Neurochem Int 119: 57-70, 2018
6)Matsumura S, Shinoda K, Yamada M, Yokojima S, Inoue M, et al: Two distinct amyloid beta-protein (Abeta) assembly pathways leading to oligomers and fibrils identified by combined fluorescence correlation spectroscopy, morphology, and toxicity analyses. J Biol Chem 286: 11555-11562, 2011
7)Watanabe-Nakayama T, Ono K, Itami M, Takahashi R, Teplow DB, et al: High-speed atomic force microscopy reveals structural dynamics of amyloid β1-42 aggregates. Proc Natl Acad Sci U S A 113: 5835-5840, 2016
8)Ono K, Condron MM, Teplow DB: Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci U S A 106: 14745-14750, 2009
9)Ono K, Tsuji M: Protofibrils of amyloid-β are important targets of a disease-modifying approach for Alzheimer's disease. Int J Mol Sci 21: 952, 2020[doi: 10.3390/ijms21030952]
oligomers induce neurotoxicity via plasma membrane damage. FASEB J 33: 9220-9234, 2019
11)Hayden EY, Teplow DB: Amyloid β-protein oligomers and Alzheimer's disease. Alzheimers Res Ther 5: 60, 2013[doi: 10.1186/alzrt226]
12)Morgan D: Immunotherapy for Alzheimer's disease. J Intern Med 269: 54-63, 2011
13)Solomon B, Koppel R, Hanan E, Katzav T: Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A 93: 452-455, 1996
14)Watanabe-Nakayama T, Tsuji M, Umeda K, Oguchi T, Konno H, et al: Structural dynamics of amyloid-β protofibrils and actions of anti-amyloid-β antibodies as observed by high-speed atomic force microscopy. Nano Lett 23: 6259-6268, 2023
15)van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, et al: Lecanemab in early Alzheimer's disease. N Engl J Med 388: 9-21, 2023
16)エーザイ: 「レケンビ®」の皮下投与製剤の中間解析結果およびClarity AD試験の追加解析から早期アルツハイマー病の初期段階の当事者様における臨床上の改善データを第16回アルツハイマー病臨床試験会議(CTAD)において発表, 2023 https://www.eisai.co.jp/news/2023/news202368.html(最終閲覧日: 2024年6月17日)
17)Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, et al: Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330: 512-527, 2023
18)Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, et al: Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis 9: 197-210, 2022
19)Vaz M, Silva V, Monteiro C, Silvestre S: Role of aducanumab in the treatment of Alzheimer's disease: challenges and opportunities. Clin Interv Aging 17: 797-810, 2022
20)Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, et al: Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol 79: 13-21, 2022
21)Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, et al: Two phase 3 trials of gantenerumab in early Alzheimer's disease. N Engl J Med 389: 1862-1876, 2023
22)Honig LS, Vellas B, Woodward M, Boada M, Bullock R, et al: Trial of solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med 378: 321-330, 2018
23)Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, et al: Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol 79: 1113-1121, 2022
24)Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, et al: Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370: 322-333, 2014
25)Perneczky R, Jessen F, Grimmer T, Levin J, Flöel A, et al: Anti-amyloid antibody therapies in Alzheimer's disease. Brain 146: 842-849, 2023
26)Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, et al: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54, 2003
27)Vellas B, Black R, Thal LJ, Fox NC, Daniels M, et al: Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 6: 144-151, 2009